TRT CardioGold 100
Cardiac Regeneration Technologies, LLC (CRT), a clinical stage company and a subsidiary of TRT, is committed to neovascularization and increasing collateral pathways within the myocardium. The use of shockwave therapy directly on the surface of the heart shows preliminary results of increased blood flow, increase in the ejection fraction and a marked improvement in cardiac performance.
Regeneration of infarcted heart muscle remained a dream of modern medicine despite of comprehensive research on stem cell and gene therapy.
Both technologies have not gained broad clinical use due to limited clinical results and significant side-effects including tumor formation.
Shockwave therapy induces tissue regeneration in infarcted heart muscle and thereby significantly improves heart function (left ventricular ejection fraction).
Shockwaves at low-energy levels are in broad clinical use for tissue regeneration in other indications, mainly in orthopedics (see International Society of Medical Shockwave Treatment – www.ismst.com). It is therefore proven safe in millions of patients over more than 30 years. This distinguishes shockwave therapy clearly from all other regenerative therapy approaches!
While establishing cardiac shockwave therapy for the intraoperative use in cardiac surgery we are in parallel developing a second generation heart applicator for minimally-invasive/ interventional use in cardiology.
This device is not yet approved for distribution or use in the United States.
Dr. Michael Grimm of the University of Vienna using CardioGold to regenerate heart tissue cells.